SBIR/STTR Research Award
INDENTIFICATION OF HUMAN F CELL GROWTH FACTOR
Award amount
$500,000Program and phase
SBIR · Phase IIAward year
1993Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Merrifield Research
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
FETAL HEMOGLOBIN CAN GREATLY REDUCE THE SYMPTONS OF HEMOGLOBIN DISORDERS SUCH AS SICKLE CELL AMEMIA AND B-THALASSEMIA DISEASES WHICH AFFECT MILLIONS OF PEOPLE WORLDWIDE. CYTOTOXIC AGENTS ARE CURRENTLY BEING USED TO ATTEMPT TO SWITCH THE ADULT PROGRAM OF HEMOGLOBIN SYNTEHSIS TO FETAL HEMOGLOBIN IN THESE PATIENTS. THERE IS A CLEAR NEED TO DEVELOP NONTOXIC AGENTS TO ACCOMPLISH THIS RESULT THERE IS ALSO STRONG EVIDENCE THAT NATURAL FACTORS EXIST WHICH ARE CAPABLE OF ACCOMPLISHING THIS IN VITRO SYSTEMS. WE WILL IDENTIFY SUCH A FACTOR OR FACTORS, WHICH WE ARE CALLING F CELL FACTOR (FCF), USING A NEW, TWO PHASE LIQUID CULTURE SYSTEM. IN THIS ASSAY SYSTEM WE WILW TEST NOT ONLY SERA FROM FETAL CALVES, WHICH HAS BEEN SHOWN TO CONTAIN SUCH A FACTOR, BUT ALSO HUMAN CORD BLOOD SERA, SERUM FROM PATIENTS WHO SHOW ELEVATED FETAL HEMOGLOBULIN, CONDITIONED MEDIA FROM CELL LINES, NON-HUMAN PRIMATE SERUM AND RECOMBINANT HEMPOIETIC GROWTH FACTORS. THIS PROJECT WILL ESTABLISH A RELIABLE ASSAY AND WILL LEAD THE WAY FOR FUTURE PURIFICATION AND CLONING OF THE FACTOR.
Technology keywords
Not reported